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Introduction: The importance of non-small cell lung cancer
(NSCLC) histologic subtype has increased during the last few
decades because of an unprecedented shift in epidemiology and an
increasing number of target-specific chemotherapeutic agents. This
review examined histology as a potential prognostic and/or predic-
tive factor of clinical outcomes in advanced NSCLC.
Methods: Literature searches of articles from 1982 to 2007 were
conducted. We identified publications detailing phase II or III
studies, retrospective analyses, and meta-analyses that reported a
statistically significant prognostic or predictive role for histology.
Results: Of 408 publications identified, 11 reported a prognostic
association between histology and clinical outcomes, and 7 sug-
gested that histologic subtype was predictive of outcomes in patients
with advanced NSCLC treated with specific cytotoxic chemotherapy
regimens. Fourteen publications reported histology was prognostic
and/or predictive in patients treated with epidermal growth factor
receptor inhibitors. Inadequate data collection, test methodology, or
study design—including insufficient sample size, misclassified sam-
ples, and grouping of histologic subtypes for analysis—may have
obscured the interpretation of the role of histology in many of the
studies.
Conclusions: Although differences in study design and analyses
make definitive conclusions difficult, evidence suggests that histol-
ogy may be prognostic or predictive of clinical efficacy outcomes.
To determine which patients would benefit from specific treatments
and to further understand the role of histology, future studies should
focus on establishing a definitive histologic diagnosis, and should
include an analysis of histologic subtypes and efficacy outcomes.
Key Words: Non-small cell lung cancer, Histology, Chemotherapy,
Prognostic, Predictive.
(J Thorac Oncol. 2008;3: 1468–1481)
Background
Slow progress continues to be made in prolonging
survival in patients with advanced non-small cell lung cancer
(NSCLC). To optimize treatment for the individual patient,
published clinical trial results regularly provide information
on prognostic factors and factors that may predict drug effect.
Historically, histologic subtype has not reliably been shown
to have prognostic importance in advanced NSCLC.1–3 Al-
though histologic subtypes are often described for patients
with NSCLC enrolled in clinical trials, analyses that examine
a potential association between histology and efficacy out-
comes are often not reported.
However, recently presented data from two random-
ized, controlled phase III trials of cytotoxic chemotherapy
have prompted a renewed interest in the impact of NSCLC
histology on efficacy outcomes. A retrospective analysis4 of a
trial comparing second-line pemetrexed with docetaxel in
NSCLC5 and a prospective analysis of a trial comparing
first-line pemetrexed and cisplatin with gemcitabine and cis-
platin in NSCLC6 identified a statistically significant treat-
ment-by-histology interaction, with longer overall survival
exhibited in patients with nonsquamous carcinoma treated
with pemetrexed and shorter survival in patients with squa-
mous cell carcinoma treated with pemetrexed. In addition, a
third randomized study comparing two doses of second- and
third-line pemetrexed in NSCLC also showed that efficacy
varied by histology.7
Given these results, we examined if previous trials of
agents other than pemetrexed had observed an association
between histology and clinical outcomes. We reviewed the
literature of the last 25 years and identified studies that
reported an association between the histologic subtype of
advanced NSCLC, patient prognosis, and/or the efficacy of
specific chemotherapeutic agents. This review summarizes
those studies, examines them in the context of the literature,
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and discusses possible reasons why histology has not been
consistently observed as a prognostic and/or predictive factor.
Finally, recommendations are made to further our under-
standing of the role of histology in the treatment of advanced
NSCLC.
Rationale
Additional rationale for examining histologic subtype
as a possible prognostic factor or predictor of treatment
efficacy in late-stage NSCLC is multifold. First, NSCLC
cellular subtypes have different embryologic origins and arise
in different anatomic locations (central versus peripheral
airways),8 and therefore might have differing capacities for
drug transport, binding, bioactivation, and metabolism. Ad-
ditionally, since certain mutations associated with NSCLC
occur more frequently in certain cell types (for example, the
ras proto-oncogene9 and epidermal growth factor receptor
EGFR mutations10 occur predominantly in lung adenocar-
cinomas), changes in cell responsiveness associated with
those mutations could follow the same pattern.
Likewise, new chemotherapies with selective targets
might have a greater impact on one histologic subtype over
another given differences in expression of the target among
cell types. For example, thymidylate synthase (TS), an en-
zyme involved in DNA biosynthesis and targeted by antime-
tabolites (such as 5-fluorouracil and pemetrexed), has higher
mRNA and protein expression in squamous cell carcinoma
compared with adenocarcinoma.11 High TS expression levels
also correlate with poor prognosis in NSCLC.12 It has been
hypothesized that low TS expression might predict better
clinical outcome in response to treatment with TS inhibitors
such as pemetrexed. Another example is ERCC1 (excision-
repair cross complementation group 1), a protein implicated
in DNA adduct repair that has higher expression in squamous
cell carcinoma.13 High ERCC1 gene expression was associ-
ated with shorter survival in samples derived from patients
with advanced NSCLC.14 Furthermore, a survival benefit for
cisplatin-based adjuvant chemotherapy has been associated
with the absence of ERCC1 protein in patients with
NSCLC.13 High tumoral expression of RRM1 (ribonucleotide
reductase subunit M1) has been shown to predict resistance of
NSCLC to gemcitabine and platinum combination therapy.15
High RRM1 expression has also been correlated with favor-
able prognoses (disease-free and overall survival) in early-
stage NSCLC, although a significant association between
RRM1 expression and histologic subtype was not observed.16
As pharmacogenomic research continues, additional genes
and proteins may be identified that are associated with effi-
cacy and safety outcomes.
NSCLC: Histologic Subtypes
The main histologic subtypes of NSCLC, as defined by
the World Health Organization (WHO), include adenocarci-
noma, squamous cell (epidermoid) carcinoma, and (anaplas-
tic) large cell carcinoma.17 The distribution of these histo-
logic subtypes has changed worldwide in the last few
decades, marked by a growing incidence of adenocarcinoma
and a concurrent decline in the incidence of squamous cell
carcinoma.18 The epidemiology, global distribution, and
causative factors associated with lung cancer have recently
been reviewed in depth.18,19
Squamous cell carcinoma has historically had the stron-
gest association with smoking, although it is believed that
design changes in cigarettes (lower tar, lower nicotine, and
side vents) have changed the anatomic location and histologic
subtype of lung cancer.20–23 Squamous cell carcinoma arises
most frequently in the proximal bronchi and tends to remain
localized. The histologic diagnosis of classic squamous cell
carcinoma is generally straightforward, with relatively exten-
sive areas of keratinization and an associated inflammatory
component, especially in lesions undergoing cavitation. Less
differentiated forms of squamous cell carcinoma, however,
have no keratinization and are made of smaller undifferenti-
ated cells. These cells may recapitulate basal cell layers of the
squamous epithelium, and, indeed, basaloid variants of squa-
mous cell carcinoma and large cell carcinoma have also been
described.24 Recently, these variants were reported to have a
significantly worse prognosis compared with conventional
squamous cell carcinoma.24 Such tumors should be distin-
guished from small cell lung carcinoma, and immunohisto-
chemistry for neuroendocrine markers or specific types of
cytokeratins may be required.
Adenocarcinoma includes a morphologically heteroge-
neous group of tumors.25,26 It is also associated with smoking,
although more and more adenocarcinomas occur in “never
smokers” (generally in young women). Patients often present
with metastatic disease before the development of symptoms.
Most of these tumors are peripheral and are related to surface
alveolar epithelium or to bronchial mucosal glands. Histo-
logic examination reveals gland formation, papillary struc-
tures, or solid growth with mucin production. One subtype of
adenocarcinoma, bronchioalveolar carcinoma (BAC), is a
more slowly growing tumor with a different clinical presen-
tation and a better prognosis compared with other adenocar-
cinomas.27,28 The histopathologic definition of BAC has un-
dergone major changes in recent years, and some confusion
exists regarding its diagnosis among different centers if the
currently proposed strict diagnostic criteria are not correctly
applied.29,30 The diagnosis of BAC is now restricted to
tumors that have a lepidic growth along pulmonary septa in
the absence of parenchymal invasion.29,30 All tumors origi-
nally diagnosed as BAC, therefore, need to be reassessed in
any retrospective study since, in past decades, the term BAC
has been applied to tumors with a remarkably different
behavior. In this context, the number of pure BAC tumors is
low and includes both mucinous and nonmucinous forms.
Additionally, because many pulmonary adenocarcinomas
have a combined pattern of growth, mixed areas of BAC and
conventional acinar or papillary adenocarcinoma may coexist
in the same tumor. Indeed, such tumors are so common that
the WHO proposed the classification “mixed subtype” for
these adenocarcinoma variants.17 The mixed subtype gener-
ally follows the behavior of conventional adenocarcinoma,
with the possible exception of tumors with a minimal inva-
sive component. One study has, in fact, shown that minimal
parenchymal invasion does not significantly alter the excel-
lent prognosis of predominantly BAC-type tumors.31
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Large cell carcinoma is the least common of the three
main subtypes of NSCLC. The criteria for its diagnosis are
not well defined and vary widely. Modified histopathologic
diagnostic criteria indicate that some tumors categorized as
large cell carcinoma should be reclassified as undifferentiated
adenocarcinoma or squamous cell carcinoma, but a lack of
morphologic features often prevents an appropriate classifi-
cation. This is especially true in advanced NSCLC, which
comprises high-grade undifferentiated primary or metastatic
tumors that are often inoperable. Thus, the histologic material
for the diagnosis is limited to small biopsy samples (of
primary or metastatic tumors), and the final tumor type
classification may not be correct. Nevertheless, the latest
WHO classification17 has dramatically changed the criteria
for “anaplastic large cell carcinomas” by introducing a sep-
arate category of “sarcomatoid carcinoma” and including
only very rare tumor subtypes (lymphoepithelial, clear cells,
and rhabdoid variants). A notable exception to the lack of
distinctive histologic criteria is the large cell neuroendocrine
carcinoma, recognized by Travis and colleagues as a distinct
tumor entity with neuroendocrine features and a clinical
behavior similar to that of small cell lung cancer.32 Large cell
neuroendocrine carcinoma should be identified using neuroen-
docrine markers and should be excluded from studies in NSCLC
because of its different biologic and clinical properties.
The biologic features and treatment sensitivity of the
rarer NSCLC subtypes, such as sarcomatoid tumors, are not
as well defined. For the purpose of analysis, these rarer
tumors are often grouped with unspecified and poorly differ-
entiated NSCLC. Mixed carcinomas, which may contain all
possible combinations of NSCLC subtypes (for example,
adenosquamous), also exist. A mixed tumor that contains a
small cell carcinoma component and a NSCLC component is
considered a small cell lung cancer combined variant and, as
such, should be excluded from NSCLC studies.
METHODS
Study Selection
This review focuses on histology in unresectable, stage
III/IV NSCLC. Literature searches were conducted using the
Scirus search engine, which contains over 450 million in-
dexed scientific items. The sources indexed by Scirus in-
clude: Medline, ScienceDirect, BioMed Central, and Nature
Publishing Group. Searches covered the interval from 1982 to
2007. Search terms included combinations of the following in
both the title and text of the article: non-small cell lung
cancer, advanced, metastatic, phase II, phase III, randomized/
randomised, controlled trial, systematic review, meta-analy-
sis, retrospective analysis, chemotherapy, predict/predictive,
prognosis/prognostic, interaction, multivariate, univariate,
Cox (proportional hazard model), histology/histologic/ histo-
type, adenocarcinoma, and squamous cell carcinoma. Articles
that were published in a language other than English and
congress abstracts were excluded.
For this review, the methods and results section of each
article were reviewed to identify any association of histology
with efficacy variables. Reference lists from each article were
searched for additional relevant publications, as were refer-
ence lists from relevant review articles. A predefined tem-
plate was used to collect information from each publication
including study design, methods, population characteristics,
and results. Compiled data were then reviewed, using each
publication as the reference source. Any discrepancies/differ-
ences found were discussed and agreed upon.
Statistical Considerations
In the context of this review, histologic subtype is con-
sidered “prognostic” when it is associated with a clinical out-
come (prognosis) independent of a given therapy. Histologic
subtype is considered “predictive” when it is associated with,
and predicts, the effectiveness of a particular treatment, i.e.,
when there is a significant treatment-by-histology interac-
tion.33,34 The presence of a significant treatment-by-histology in-
teraction indicates that the treatment effect (for example, the
hazard ratio for survival) varies according to the histologic
diagnosis. That is, the combination of the treatment and the
histologic diagnosis affects the efficacy outcome (such as sur-
vival). For the exploratory purpose of this review, a 0.10 signif-
icance level was chosen, regardless of what level each publica-
tion used, to have a standard definition to apply across all
studies. Studies that evaluated different doses of the same
therapy (without a control arm) are not informative in ascertain-
ing a predictive association and were not considered in this
review.
In the tables presented in this review, the results for
prognostic factors are reported using univariate analyses and/or
multivariate analyses, and predictive factors are reported using
multivariate analyses (as multivariate analyses are required to
assess an interaction effect); these results were compiled from
those reported in each publication. Although histology may have
a prognostic and/or predictive association in each of the selected
studies, in some cases, other factors (such as disease stage,
gender, performance status, or prior therapy) may have been
reported to have a greater impact than histology; however, these
factors are not summarized in this review.
RESULTS
We identified 408 publications that contained the
search terms. Of these 408 publications, we excluded those
that had not tested for a prognostic or predictive role for
histology. Also excluded were publications that examined
this relationship but reported no statistically significant evi-
dence. This review summarizes 32 publications that reported
a statistically significant association between histology and
one or more efficacy parameters.
Of the publications reporting an association between
histology and treatment outcome, 14 summarized studies of
tyrosine kinase inhibitors. These papers were examined sep-
arately. The remaining 18 publications on cytotoxic chemo-
therapy were divided into two groups: those that examined
the association of histology with efficacy variables in a single
population, and those that examined this relationship com-
paring two or more populations or treatment arms. The two
groups of chemotherapy publications are discussed in the
next two sections and are summarized in Tables 1 and 2. The
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TABLE 1. Single-Arm or Pooled Population Studies Showing NSCLC Histologic Subtype as a Possible Prognostic and/or
Predictive Factor of Clinical Outcomes
Study (First
Author, Date
of Publication) Treatment Armsa (n)
Observed Histology
Subtypes
(% of Each)b Histology Results Conclusions
Retrospective analyses of patient data pooled from multiple sites and/or multiple years
Charloux,
199735
First-line CT and/or RT;
(n  141 unresected
stage IIIA/B/IV)
For pts at all disease
stages:
Adeno (16)
SQ (73)
BAC (7)
LC (4)
Median OS (mo): BAC: 12.5; SQ: 6.8;
LC: 6.5; Adeno: 4.9 (p  0.042).
Multivariate analysis: relative risk for
Adeno 1.47 (with SQ as reference)
(p  0.087); relative risk for BAC
0.47 (p  0.056).
BAC associated with  OS; Adeno
associated with  OS.
Martins, 199936 First-line CP-based CT,
RT, surgical procedures
(n  616 stage IV)
Adeno-BAC (41)
SQ (37)
BAC (5)
LC (4)
Poorly-differentiated
(13)
Multivariate analysis: OS HR for Adeno
[0.76, p  0.0080] and poorly
differentiated [0.68, p  0.0079] 
SQ [1.00], indicating  OS.
HR for LC [1.54, p  0.0514] showed
trend for  OS.
Adeno and poorly differentiated
associated with  OS over SQ.
Itaya, 200737 First-line Cb  PTX
(n  98)
Adeno (76)
Non-Adeno (24)
Multivariate analysis: OS (but not PFS)
 for Adeno over
Non-Adeno (2-yr survival rate 40% vs
15%, p  0.0017).
Adeno associated with  OS.
Shinkai, 199238 First-line CT: CP 
VIND, VIND  MIT,
or CP  VIND  MIT
(n  192)
Adeno (70)
SQ (18)
LC (9)
Adeno-SQ (3)
Univariate analysis: SQ favorable for
tumor response (p  0.017).
Multivariate analysis: histology not
associated with tumor response.
SQ associated with  tumor
response (in univariate analysis).
Finkelstein,
198639
First-line CT: one of
seven combination
regimens (n  893)
Adeno (43)
SQ (36)
LC (19)
Other (2)
Multivariate analysis: Non-LC
associated with  1-yr survival.
Non-LC associated with  survival.
Analyses of patient data from clinical trials with either a single arm (phase II) or multiple pooled arms (phase III)
Ceresoli,
200440
Second-line weekly
PTX (n  53)
Non-SQ (70)
SQ (30)
 PFS for Non-SQ (p  0.004).
Multivariate analysis: Clinical benefit
(CRPRSD)  for Non-SQ over
SQ (p  0.03, OR  1.37).
Non-SQ associated with  clinical
benefit and PFS.
LeCaer, 200741 First-line weekly
DTX (n  50)
Adeno (40)
SQ (48)
Undifferentiated (12)
Univariate analysis: Histology (unstated
cell type) associated with  OS.
Multivariate analysis: no correlation
between histology and OS.
Histology associated with  OS (in
univariate analysis).
Weiss, 200742 Pooled arms: second-line
DTX vs PEM (n 
571)
Adeno (52)
SQ (30)
Other (18)
Univariate analysis: OS  for Adeno
over SQ or Other (9.1 vs 6.5 vs 7.8
mo, p  0.004).
Multivariate analysis: for the same
comparison, p  0.054.
Adeno associated with  OS.
Fukuoka,
199143
Pooled arms: CP  VIND
vs CP  VIND  MIT
vs CP  VIND  MIT
 ETO (n  203)
Adeno (48)
SQ (43)
LC (8)
Multivariate analysis: SQ associated
with  tumor response (p  0.0428),
but not OS.
SQ associated with  tumor
response.
Rapp, 198844 Pooled arms: Group A:
VIND  CP vs CYP 
DOX  CP vs BSC
(n  137)
Adeno (45)
SQ (29)
LC (22)
Other (4)
Multivariate analysis: Histology
associated with OS (p  0.022), with
SQ associated with  median OS
than Adeno or LC.
SQ associated with  median OS.
Saynak, 200545 Pooled arms: CP  ETO
with sequential or
concurrent RT
(n  132)
Adeno (25)
SQ (73)
LC (2)
Univariate and multivariate analysis:
Non-SQ associated with  OS
(p  0.04).
Non-SQ associated with  OS.
a Data reported for stage IIIB/IV patients unless otherwise noted. Some cytotoxic chemotherapeutic agents reported in this summary table are no longer considered active in
advanced NSCLC.
b For studies with two or more arms, the percent of patients with tumors of each histology subtype is reported as a rounded average of the arms.
Adeno  adenocarcinoma, BAC  bronchioalveolar carcinoma, BSC  best supportive care, Cb  carboplatin, CP  cisplatin, CR  complete response, CT  chemotherapy,
CYP  cyclophosphamide, DOX  doxorubicin, DTX  docetaxel, ECOG  Eastern Cooperative Oncology Group, ETO  etoposide, HR  hazard ratio, LC  large cell
carcinoma, momonths, MITmitomycin, NCIC National Cancer Institute of Canada, NS not specified, OR odds ratio, OS overall survival, PEM pemetrexed, PFS
progression-free survival, PR  partial response, pts  patients, PTX  paclitaxel, RT  radiotherapy, SD  stable disease, SQ  squamous cell carcinoma, VIND  vindesine,
VNR  vinorelbine, vs  versus.
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TABLE 2. Comparative Studies Identifying Histology as a Possible Predictor of Clinical Outcomes
Study (First
Author, Date
of Publication) Treatment Armsa (n)
Observed Histology
Subtypes
(% of Each)b Histology Resultsc Conclusions
Analyses of data from trials of cytotoxic chemotherapeutic agents
Ardizzoni,
200746
First-line CP-containing
regimen (n  1489) vs
Cb-containing regimen
(n  1479)
Non-SQ (62)
SQ (38)
Non-SQ, Cb associated with  mortality
(HR  1.12, 95% CI: 1.01–1.23).
SQ: Cb not associated with mortality
(HR  0.97, 95% CI: 0.85–1.10)
(interaction p  0.098). OR for
nonresponse (Cb vs CP) 1.58 (95%
CI: 1.27–1.97) for Non-SQ and 1.10
(95% CI: 0.85–1.43) for SQ
(interaction p  0.046).
In meta-analysis, Non-SQ predictive
of  odds of tumor response and
 risk of mortality for Cb-
containing regimens.
Rudd, 200547 First-line GEM  Cb (n
 212) vs MIT  IFO
 CP (“MIC”) (n 
210)
Adeno (35)
SQ (41)
Other (24)
“Other”:  OS for GEM  Cb over
MIC.
Adeno: trend favoring GEM  Cb.
SQ: no difference between treatments
(interaction p  0.10).
“Other” histology, and possibly
Adeno, may predict  OS to
GEM  Cb.
Georgoulias,
200148
First-line CP  DTX (n
 205 evaluable) vs
GEM  DTX (n  201
evaluable)
Adeno (35)
Non-Adeno (65)
Non-Adeno  response to CP  DTX
(40.4%) than GEM  DTX (27.6%)
(p  0.028).
Adeno  response to GEM  DTX
(43.2%) than CP  DTX (23.2%) (p
 0.011). Significant treatment-by-
histology interaction for response (p-
value not reported).
Non-Adeno predictive of  tumor
response to CP  DTX; Adeno
predictive of  response to
GEM  DTX.
Cellerino,
199149
First-line CYP  EPI 
CP alternating with
MTX  ETO  LOM
(n  62) vs BSC
(n  61)
Adeno (32)
SQ (60)
LC (8)
Non-SQ:  OS for CT over BSC (9.0
vs 3.9 mo, p  0.041).
SQ: same OS in both arms (6.0 vs 5.6
mo, p  0.94). Formal test of
treatment-by-histology interaction not
presented.
Non-SQ may predict  OS for CT
regimens.
Veronesi
198850
First-line CYP  ADR 
MTX  ProC
(“CAMP”) (n  62) vs
CP  ETO (n  71)
SQ (68)
Adeno (28)
LC (3)
Unclassified (2)
SQ:  response to CP  ETO over
CAMP (45 vs 22%).
Adeno: similar response to both
treatments.
Mantel-Haenszel chi-square (adjusted for
histology) p-value  0.08.
SQ may predict  tumor response
for CP  ETO.
Analyses of data from trials of induction chemotherapy
Kim, 200251 Induction CT (CP  ETO
 VIN) then RT (n 
53) vs RT alone (n 
48) (All pts stage
IIIA/B)
Adeno (18)
SQ (74)
Other (8)
Non-SQ: median OS  for induction
CT over RT (14.0 vs 3.6 mo, p 
0.027).
SQ: median OS same for both groups
(11.6 mo vs 9.4 mo, p  0.853).
Formal test of treatment-by-histology
interaction not presented.
Non-SQ may predict  OS for CP
 ETO  VIN induction CT prior
to RT.
Huang, 200752 Induction CT (platinum 
taxane) then RT  CT
(n  127) vs RT  CT
(n  138) (All pts
locally advanced)
SQ (34)
Adeno (39)
LC (4)
Unclassified/Other
(23)
Induction CT associated with  OS for
Non-SQ (Adeno or LC) (5-yr rate
24% vs 8%, p  0.0033), but not SQ
(p  0.29).
Formal test of treatment-by-histology
interaction not presented.
Non-SQ may predict  OS for
platinum  taxane induction CT
prior to RT.
a Data reported for stage IIIB/IV patients unless otherwise noted. Some cytotoxic chemotherapeutic agents reported in this summary table are no longer considered active in
advanced NSCLC.
b The percent of patients with tumors of each histology subtype is reported as a rounded average of the arms. Due to rounding, percents may not total 100%.
c For the purpose of this review, a 0.10 significance level was selected to consider a test of interaction significant, regardless of what level the publication used, in order to have
a standard definition across studies.
Adeno  adenocarcinoma, ADR  adriamycin, BSC  best supportive care, Cb  carboplatin, CI  confidence interval, CP  cisplatin, CT  chemotherapy, CYP 
cyclophosphamide, DTX  docetaxel, EPI  epirubicin, ETO  etoposide, GEM  gemcitabine, HR  hazard ratio, IFO  ifosfamide, LC  large cell carcinoma, LOM 
lomustine, MIT  mitomycin, mo  months, MTX  methotrexate, OR  odds ratio, OS  overall survival, ProC  procarbazine, RT  radiotherapy, SQ  squamous cell
carcinoma, VIN  vinblastine, vs  versus.
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tyrosine kinase inhibitor publications are discussed in the last
section of the Results and are summarized in Table 3.
Histology as a Potential Prognostic Factor in
Single-Arm or Pooled Population Studies
Eleven studies in the last 25 years have associated
histology with clinical outcome in late-stage NSCLC.35–45 As
summarized in Table 1, these studies are of 3 types: (1)
retrospective analyses of pooled patient data, often generated
outside of a clinical trial setting (first section of Table 1); (2)
phase II clinical trial data without a comparator arm; (3)
phase III clinical trial data in which data from the arms are
pooled. (The phase II and III clinical trial data are listed
together in the second section of Table 1.) Although each of
the studies assigned a prognostic role for histology, because
of the design of the studies and/or the types of analyses, it is
unknown if the association between histology and clinical
outcome is independent of treatment (prognostic) or predic-
tive of the efficacy of a particular treatment. Given this
uncertainty, the following discussion of these studies and the
summary in Table 1 use general terms to describe the asso-
ciation instead of the terms “prognostic” and “predictive.”
In each of the retrospective analyses listed in the first
section of Table 1, histology was associated with clinical
outcome in an unresectable, locally advanced or metastatic
NSCLC patient population. Patients were either treated at a
single institution or within a cooperative group of institutions.
In the first five studies listed, patients were treated with
standard palliative care (as defined at the time of the
study),35,36 with a combination of a platinum plus other
drug(s),37,38 or with one of seven combination cytotoxic
chemotherapy regimens.39 Despite the difference in treat-
ments and the span of years covered by these studies, all of
the studies except Shinkai38 found that adenocarcinoma or a
subtype of adenocarcinoma was associated with better clini-
cal outcome. In the Finkelstein analysis, the better outcome
was extended to all nonlarge cell subtypes39; in the Charloux
analysis, the better outcome was associated with the BAC
subtype, but not with all other adenocarcinomas.35
In addition to the retrospective analyses of pooled
patient data, Table 1 summarizes six clinical trials that also
identified an association between histology and clinical out-
come.40–45 In a multivariate analysis, the Ceresoli study
found that nonsquamous histology was associated with clin-
ical benefit (CR  PR  SD) in patients receiving weekly
second-line paclitaxel.40 In a similar study in patients receiv-
ing weekly first-line docetaxel, histology was associated with
clinical outcome in a univariate analysis, but the association
was no longer observed in a multivariate analysis.41
The Weiss, Fukuoka, and Rapp studies were all multi-
ple-arm trials that combined treatment arms for the analysis
of histology associated with clinical outcome (Table 1).42–44
In a retrospective analysis42 of the phase III clinical trial
comparing pemetrexed versus docetaxel,5 adenocarcinoma
was associated with improved survival. The patients partici-
pating in the Fukuoka study all received cisplatin; in addition,
patients received vindesine on one arm, vindesine plus mit-
omycin on another arm, and vindesine, mitomycin, and eto-
poside on a third arm. In a multivariate analysis, squamous
cell carcinoma was associated with improved response.43 In a
trial by Shinkai, which reproduced two of the vindesine-
containing treatment arms of the Fukuoka trial, squamous cell
carcinoma was associated with tumor response in a univariate
analysis; however, in a multivariate analysis, only the number
of metastatic sites was a significant baseline factor affecting
tumor response.38
In the analysis by Rapp et al.,44 squamous cell carci-
noma was associated with shorter survival for a pooled group
of two cisplatin-containing treatment arms and a best sup-
portive care (BSC) arm (Table 1). Although one of the two
treatment arms (cisplatin plus vindesine) duplicated one of
the three arms in the Fukuoka study, the results differed in
that the Rapp study concluded that squamous cell carcinoma
was associated with shorter survival and the Fukuoka study
concluded that squamous cell carcinoma was associated with
improved response with no effect on survival. This difference
underscores the difficulty of interpreting results obtained by
combining multiple treatment arms.
Histology as a Potential Predictor of Clinical
Outcome in Comparative Studies
Seven studies were identified that found, through com-
parative analysis, that histology may predict efficacy out-
comes to specific chemotherapy regimens (Table 2).46–52 The
studies summarized in Table 2 are limited to those that
provided statistically significant evidence that histologic sub-
type may predict outcomes to conventional chemotherapeu-
tics. Studies are included that did not report a formal test of
treatment-by-histology interaction. For those studies for
which a treatment-by-histology interaction was not reported
but there appeared to be a differential treatment effect by
histology, we concluded that there may be a predictive
association; however, a formal assessment of a treatment-by-
histology interaction would have been more informative.
The first part of Table 2 lists studies of cytotoxic
chemotherapeutic agents, with four of these studies compar-
ing two chemotherapy regimens,46–48,50 and the study by
Cellerino et al.49 comparing a combination therapy and BSC.
Although the studies listed in Table 2 primarily examine data
from two-arm clinical trials, the first entry is a meta-analysis
of 9 randomized clinical trials (n  2968) comparing cispla-
tin- versus carboplatin-containing regimens.46 This meta-
analysis found histology was predictive of a survival advan-
tage, with carboplatin-containing regimens associated with
lower odds of tumor response and a higher risk of mortality
for patients with nonsquamous tumors. Statistically signifi-
cant tests of treatment-by-histology interaction (interaction
test p value  0.098 for survival, p  0.046 for response)
confirmed the predictive effect of histology on survival and
tumor response.
In a phase III study comparing two platinum-containing
treatment arms, the same trend was not observed as in the
Ardizzoni meta-analysis. Rudd et al.47 found that histology
characterized as “Other” (that is, tumors that were neither
adenocarcinoma nor squamous cell carcinoma), and possibly
adenocarcinoma, may predict longer overall survival for
carboplatin plus gemcitabine over cisplatin, mitomycin, plus
ifosfamide (interaction test p value  0.10).
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In a study by Georgoulias et al.48 (n  406), histology
was predictive for 2 treatment regimens: cisplatin plus do-
cetaxel and gemcitabine plus docetaxel (Table 2). Patients
with adenocarcinoma exhibited significantly greater response
to gemcitabine plus docetaxel, whereas patients with nonade-
nocarcinoma exhibited significantly greater response to cis-
platin plus docetaxel, with a significant treatment-by-histology
interaction test for tumor response (interaction test p value
not reported). Although histology was predictive of tumor
response, additional analyses determined that histology was
not predictive of survival or progression-free survival.
A retrospective data analysis of the Cellerino trial
found that nonsquamous carcinoma may predict longer sur-
vival for patients treated with the chemotherapy regimen
versus BSC (Table 2).49 In contrast, patients with squamous
cell carcinoma had the same median overall survival in both
treatment arms. This conclusion is tentative because of the
lack of a formal treatment-by-histology interaction test and
the small size of the trial. The results of the Veronesi study
(n  133) also suggested that histology may predict tumor
response; the test for association between treatment and
response, adjusted for histology, resulted in a p value of
0.08.50 In this study, patients with squamous cell carci-
noma had double the response rate to cisplatin plus eto-
poside compared with a four-drug combination regimen
(44.7% versus 21.6%), whereas patients with adenocarci-
noma had a comparable response to both treatments
(23.5% versus 27.3%).
A separate section of Table 2 summarizes the possible
predictive role of histology in two studies of induction ther-
apy.51,52 In both of these studies, specific induction chemo-
therapy regimens before radiation preferentially extended
survival for patients with nonsquamous histology. In contrast,
patients with squamous cell carcinoma did not experience any
survival benefit from induction therapy. A third study showed
a similar trend, but did not reach statistical significance.53
Although differential treatment effects were observed within
the histology subtypes in these studies, a formal test of
treatment-by-histology interaction, which could have con-
firmed histology as a predictive factor, was not reported. In a
study by Saynak et al.45 (Table 1), patients received similar
chemotherapy with concomitant and sequential radiation. In
this study, nonsquamous histology was associated with
shorter survival; however, “predictiveness” could not be
assessed because the treatment arms were pooled for the
statistical analysis.
Histology as a Prognostic and/or Predictive
Factor of Clinical Outcomes to Tyrosine Kinase
Inhibitors
Consistent evidence of an association between histol-
ogy and clinical outcome following treatment with EGFR
tyrosine kinase inhibitors was found in the 14 publications of
13 studies summarized in Table 3.54–62,64–68 The first 11
studies showed that adenocarcinoma was associated with
superior response rates, disease control rates, progression-
free survival, and survival in patients with advanced NSCLC,
but squamous cell carcinoma or a pooled group of all non-
adenocarcinoma subtypes was not.54–62,64,65 In one study, the
BAC subtype was examined separately and was associated
with a significantly higher tumor response rate than other
adenocarcinoma subtypes.65 In all 11 of these studies, the
patients were treated with the tyrosine kinase inhibitor, ge-
fitinib, suggesting that adenocarcinoma may predict better
efficacy outcomes for this agent; however, since all 11 studies
lacked a nongefitinib comparator arm, this predictive associ-
ation cannot be assessed.
The study by Thatcher et al.66 also reported that ade-
nocarcinoma may predict improved efficacy outcomes in
patients with advanced NSCLC treated with gefitinib (Table
3). The large (n  1692) prospectively randomized trial
compared gefitinib with placebo. Although the differences in
survival between the gefitinib and placebo arms did not reach
significance in the primary log-rank test in either the overall
or adenocarcinoma population, a prospectively defined Cox
regression analysis suggested significance in favor of ge-
fitinib for both the overall (p  0.03) and adenocarcinoma
(p  0.033) populations. Furthermore, an exploratory sub-
group analysis showed a higher response rate for gefitinib
versus placebo in patients with adenocarcinoma; patients with
nonadenocarcinoma did not exhibit a higher response for
gefitinib versus placebo. These analyses suggest that there is
a differential treatment effect, stronger in the adenocarcinoma
subtype than in the nonadenocarcinoma subtype; however, a
formal test of treatment-by-histology interaction was not
reported.66
The last two publications listed in Table 3 are analyses
of the phase III trial of another tyrosine kinase inhibitor,
erlotinib, versus placebo in patients who failed previous
therapy.67,68 In the original analysis, adenocarcinoma was
associated with better response and survival in a pooled
population of patients treated with placebo or erlotinib.67 In
an exploratory univariate analysis of the same study, Johnson
et al.68 showed that squamous carcinoma and adenocarci-
noma may both predict superior survival in erlotinib-treated
patients; however, a formal test of treatment-by-histology
interaction was not reported. Of note, the analysis in the
original publication categorized histology as adenocarcinoma
versus nonadenocarcinoma, whereas the analysis by Johnson
et al. used the categories of adenocarcinoma, squamous cell
carcinoma, and “other.” The difference in how squamous cell
carcinoma was grouped for the analyses may account for the
slightly different results.
DISCUSSION
Prompted by recent data from three randomized trials
that identified an association between histology and treatment
outcomes in advanced NSCLC,4,6,7 we examined the litera-
ture of the last 25 years to determine if other studies had also
observed this relationship. Historically, histology has not
been clearly or consistently described in the literature as a
prognostic or predictive variable in advanced NSCLC stud-
ies. As reflected in this review of the published literature, the
data are inconsistent with some studies suggesting more
favorable outcomes for patients with adenocarcinoma or
nonsquamous histologies, and other studies suggesting more
favorable outcomes for patients with squamous cell carci-
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noma. Although substantial differences in study design and
analyses make such specific conclusions regarding the prog-
nostic and predictive role of histology difficult, some studies
were identified in which histology was associated with clin-
ical outcomes. We identified 11 single-arm or pooled popu-
lation studies that identified an association between histology
and clinical outcomes in late-stage NSCLC (Table 1).35–45 In
each of the 11 studies, the design of the study and/or type of
analyses did not allow us to clearly distinguish between a
prognostic or predictive association. In some cases, histology
may have had both a prognostic and predictive role. Seven
additional comparative studies found that histologic subtype
may predict the efficacy outcomes of specific conventional
cytotoxic chemotherapies (Table 2),46–52 and 14 publications
of 13 studies found histology was prognostic and/or predic-
tive in patients treated with EGFR tyrosine kinase inhibitors
(Table 3).54–62,64–68 Although the literature search under-
taken for this review article was extensive, additional publi-
cations may exist that support or contradict an association
between histology and efficacy outcomes.
The most consistent link between histology and treat-
ment outcome was found for EGFR tyrosine kinase inhibitors
(Table 3).54–62,64–68 Interestingly, the association between
adenocarcinoma and improved efficacy in patients treated
with EGFR inhibitors was not an anticipated result; rather, it
was initially hypothesized that the better outcome would
correlate with squamous cell carcinoma, in which EGFR is
highly expressed.69,70 More recent data suggest that the effi-
cacy of EGFR tyrosine kinase inhibitors may be linked to
their ability to block aberrant EGFR pathway signaling asso-
ciated with activating receptor mutations,71,72 or that it may
correlate with increased EGFR gene copy number.62 Despite
the lack of a definitive understanding of the mechanism of
action of EGFR inhibitors, adenocarcinoma histology can be
used to identify those patients more likely to benefit from
EGFR tyrosine kinase inhibitors.
A limitation of this review, as with any review or
meta-analysis, is publication bias. Publication bias occurs
when negative results (negative histology results in our case),
which are often not published, are excluded. Analyses of
efficacy by histologic subtype may not be reported for several
reasons: the histology data were not collected; analyses were
not performed because the study was inadequately powered
or because historical evidence suggested such analyses were
not important; analyses were performed but results were
negative (and/or inconsistent across other endpoints) and
therefore not reported; or results of analyses were positive but
not reported because it was unclear how to interpret the
findings.
Although many trials do not report treatment-by-histol-
ogy analyses, while reviewing the search results, publications
were identified that examined this relationship and found no
significant association. A number of these publications ana-
lyzed phase III clinical trial data.53,73–85 Several of these
studies combined treatment arms for the analysis of histologic
subtypes and efficacy outcomes, thus precluding identifica-
tion of a predictive relationship. Additionally, many of these
studies were relatively small (100–200 patients per treatment
arm), and did not have adequate statistical power to detect an
interaction. Several phase II studies were identified that also
reported no association between histology and efficacy out-
comes. Given the limited sample size of phase II studies,
these findings were not unexpected.
There are multiple reasons why some studies that ex-
amined histology as a prognostic/predictive factor did not
observe an association. The most obvious reason is that the
study might have correctly concluded that histology is neither
significantly prognostic nor predictive of efficacy outcomes.
This might especially be true for studies investigating a
predictive role for cytotoxic chemotherapy agents that affect
structures (for example, enzymes or receptors) equally com-
mon to all cells.
Another reason that histology may fail to be identified
as a prognostic or predictive factor is that the study design,
study population, and/or statistical analyses are inadequate
for this purpose. For example, meta-analyses, which combine
results from different trials with various treatments and pa-
tient demographics, can obscure differences among various
subgroups of patients.84 Analyses that combine treatment
arms can result in different conclusions than those that
examine the arms separately; by definition, the former may
only examine for prognostic significance whereas the latter
may identify predictive effects. As an example, following the
pivotal phase III study of second-line pemetrexed compared
with docetaxel,5 a retrospective analysis by Weiss et al.42
pooled the treatment arms and reported a prognostic role for
histology. However, in a second set of retrospective analyses
recently presented for the same study, the treatment arms
were evaluated separately and histology was predictive of a
differential treatment effect for pemetrexed.4 Study features
may also obscure specific histology findings. For example,
subtle differences in the proportion of patients with specific
baseline characteristics, such as performance status, disease
stage, or adenocarcinoma, squamous cell carcinoma, or large
cell carcinoma, may skew a study’s results, making it easier
or more difficult to find histology effects.
In many studies, inadequate study design equates with
insufficient sample size. The requirement for sample size
when testing for interaction (with time to failure as the
outcome) is approximately four times larger than that needed
to detect a main effect of the same magnitude, even with
some favorable assumptions.86,87 Of note, the studies that
observed a predictive effect, with a significant treatment-by-
histology interaction, were often relatively large trials.46–48
An insufficient sample size may also lead to the combination
of histologic subtypes, which could obscure a significant
effect in a relatively uncommon histologic subtype (for ex-
ample, large cell carcinoma).
Even within a morphologically defined histologic sub-
type, such as adenocarcinoma, multiple subtypes can exist,
each associated with a different prognosis and/or responsive-
ness to a particular drug. When these subtypes are analyzed
together, the better prognosis or responsiveness of some
subtypes may be diluted by the poorer prognosis and nonre-
sponsiveness of others, thus obscuring the advantage of
specific histologic subtypes. For example, Charloux et al. and
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Miller et al. concluded that BAC is associated with improved
outcome,35,65 yet most studies combine this subtype (which
often is present in relatively few patients) with other adeno-
carcinomas, thereby possibly masking its responsiveness.
Similarly, because generally less than 10% of patients have
large cell carcinoma (as shown in Tables 1 through 3), the
grouping of large cell carcinoma with either adenocarcinoma
or squamous cell carcinoma may also affect conclusions
regarding the prognostic role of histology.
Additional evidence for differential responsiveness
within the adenocarcinoma subtype has been shown in gene
profiling studies.88–90 In these studies, the investigators found
that each morphologic classification exhibited a unique pat-
tern of gene expression, but there was heterogeneity in the
gene profile within the adenocarcinoma classification such
that the tumors could be subdivided further into multiple
subtypes (three in one study, four in the other). Each subtype
expressed unique genes characteristic of specific morphologic
variants such as neuroendocrine or type II pneumocytes.
Interestingly, both investigators showed that the median sur-
vival of the adenocarcinoma subtypes differed. Likewise,
gene profiling has shown heterogeneity within the squamous
cell carcinoma subtype, with two subclasses detected that
differed in survival.91,92 These results provide additional
evidence that further subdivision (defined either by histology or
pharmacogenomic markers) of the adenocarcinoma and squa-
mous cell carcinoma subtypes may be necessary to ascertain
differences in prognosis and/or drug responsiveness.
A significant number of misclassified tumors within a
study may also obscure the prognostic or predictive role for
histology. As the definition of NSCLC histologic subtypes
has evolved in recent years, the new criteria may not be
equally applied across clinical institutions, potentially yield-
ing misclassified tumors. Studies in which inter-reviewer
variability was examined suggest that this is higher in the case
of undifferentiated tumors (such as large cell carcinoma).93,94 Also,
the tumor sampling method can affect the accuracy of the
results. Diagnoses based on cytology specimens are limited
because of a lack of information on tumor architecture. In a
study comparing diagnoses obtained from bronchial biopsy
samples versus thoracotomy samples, there was good agree-
ment (  0.70) between the 2 sample methods, with con-
flicting results most frequently seen in bronchial biopsy
specimens that had necrotic sections and an absence of
differentiation.94 Furthermore, diagnoses made from bron-
chial biopsies or limited surgical sections may also lead to
inaccurate results because of tumor heterogeneity. In a study
by Roggli et al.,95 major tumor heterogeneity was observed in
45% of the carcinomas studied.
Conclusions and Recommendations
This review examined the impact of NSCLC histology
on clinical outcomes. Given the development of targeted
therapies and the refinement of histologic classifications,
more studies should include an analysis of histologic sub-
types and their association with efficacy outcomes. The need
for these analyses is even greater given that the incidence of
adenocarcinoma has markedly increased, thus requiring treat-
ment options that are particularly effective in these tumors.
For some treatments, tumor histology, in addition to a grow-
ing panel of biomarkers, has the potential of delineating
which patients will benefit, thus allowing patients to avoid
unnecessary exposure and the associated risk of toxic side
effects. Additionally, since one connection between histo-
logic subtype and toxicity has been identified recently (i.e.,
patients with squamous cell tumors are at risk for hemor-
rhagic complications when treated with bevacizumab),96 fu-
ture studies should also include an analysis of the association
between histologic subtypes and clinically relevant toxicities.
As our reliance on histologic subtype for determining
optimal treatment increases, so does the importance of a
definitive histologic diagnosis. Future studies should consider
a central pathology review or another related method for
verifying histologic diagnosis. Furthermore, given the multi-
ple distinct histologic subtypes within adenocarcinoma, BAC
and any other subtype with distinct pathologic features should
be separately analyzed when possible. Additionally, large cell
neuroendocrine carcinomas are more appropriately analyzed
with small cell lung cancer rather than in the large cell
carcinoma/NSCLC category.
As new trials in NSCLC are designed, consideration
should be given to the randomization process. When possible,
whether by minimization or stratification, randomization
should consider factors for histology in addition to the well-
known prognostic factors of gender, disease stage, perfor-
mance status, and smoking history. Most of the studies
presented in this review demonstrated associations between
these well-known prognostic factors (in addition to histologic
factors) and efficacy outcomes.
To assess the true predictive association between treat-
ment and histology, inclusion of a formal treatment-by-
histology interaction test is recommended.33,34 Testing the
hypothesis of no treatment effect within different histologic
subtypes does not determine if treatment effect varies by
histology; it only determines if a treatment effect exists
among various histologic subtypes.33 In addition, such anal-
yses of treatment effect within histologic subtypes ignore the
variability between the subtypes.33 These issues are properly
addressed by assessing treatment-by-histology interaction in
multivariate analyses. Tests of interaction can be performed
using standard statistical software (such as SAS), and usually
require a statistician to define the interaction term and statis-
tical model correctly. In addition to reporting tests of inter-
action, the reporting of treatment effects (such as medians
and/or hazard ratios with 95% confidence intervals) in each
major histologic subtype (adenocarcinoma, squamous cell
carcinoma, large cell carcinoma, and all other subtypes),
when feasible, is encouraged. This illustrates the survival
pattern across histologic subtypes (i.e., determines which
subtypes have longer or shorter survival) and the relative
effects of treatment within histologic subtypes.
To assess treatment-by-histology interactions, large
studies are needed, often as much as four times larger, to
detect an interaction compared with a main treatment ef-
fect.86,87 Most studies lack adequate power to detect an
interaction, if one exists. Recognizing that it is often not
practical to design trials to assess formal treatment-by-histol-
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ogy interactions, researchers should continue to prespecify or
retrospectively assess the effects of baseline patient and
disease factors on efficacy and safety (including a formal
assessment of interactions with treatment). As we progress
toward targeted-patient care, such analyses will help identify
patients who are candidates for specific therapies.
The need for improved efficacy outcomes drives the
search and refinement of active agents in NSCLC. Tumor
histology promises to be another area in which drug efficacy
may be improved. Given the introduction of more targeted
agents and a refinement in histologic classifications, the
examination of tumor histology and its association with
efficacy outcomes may aid in maximizing survival in patients
with NSCLC.
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